Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions. A new product launch represents one of ...

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and ...

The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines. Novo Nordisk and Septerna have ...

While the pharma industry has openly embraced AI, there are still serious concerns related to the use of the technology with health data. Primarily, AI relies on collecting massive amounts of data in ...

The organization believes that the proposed cuts will be harmful to Americans suffering from mental illnesses. A key talking point for the current administration is funding for Medicare and Medicaid.